observed that the DLAT was substantially upregulated in gastric cancer (38), while the FDX1 was decreased in lung adenocarcinoma (39), both of which are implicated in tumor progression by influencing tumor metabolic pathways. This evidence concerns the gene FDX1 and neoplasm.